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Abstract
Background: Different isoforms of Cytochrome P450 (CYP) metabolized different types of substrates (or drugs 
molecule) and make them soluble during biotransformation. Therefore, fate of any drug molecule depends on how 
they are treated or metabolized by CYP isoform. There is a need to develop models for predicting substrate specificity 
of major isoforms of P450, in order to understand whether a given drug will be metabolized or not. This paper 
describes an in-silico method for predicting the metabolizing capability of major isoforms (e.g. CYP 3A4, 2D6, 1A2, 2C9 
and 2C19).
Results: All models were trained and tested on 226 approved drug molecules. Firstly, 2392 molecular descriptors for 
each drug molecule were calculated using various softwares. Secondly, best 41 descriptors were selected using 
general and genetic algorithm. Thirdly, Support Vector Machine (SVM) based QSAR models were developed using 41 
best descriptors and achieved an average accuracy of 86.02%, evaluated using fivefold cross-validation. We have also 
evaluated the performance of our model on an independent dataset of 146 drug molecules and achieved average 
accuracy 70.55%. In addition, SVM based models were developed using 26 Chemistry Development Kit (CDK) 
molecular descriptors and achieved an average accuracy of 86.60%.
Conclusions: This study demonstrates that SVM based QSAR model can predict substrate specificity of major CYP 
isoforms with high accuracy. These models can be used to predict isoform responsible for metabolizing a drug 
molecule. Thus these models can used to understand whether a molecule will be metabolized or not. This is possible 
to develop highly accurate models for predicting substrate specificity of major isoforms using CDK descriptors. A web 
server MetaPred has been developed for predicting metabolizing isoform of a drug molecule http://crdd.osdd.net/
raghava/metapred/.
Background
Metabolism determinates the fate of a compound enter-
ing inside the body. Ideally, drugs are broken down to
harmless soluble metabolites that are easily excreted
through urine or bile [1]. Drug metabolism is a process,
which play vital role in pharmacokinetics and therapeutic
action of drug molecules [2]. Cytochrome P450 enzymes
(CYPs) are a multi gene family of heme-containing isoen-
zymes that are involved in oxidative metabolism of drug,
steroids and carcinogens. About sixty CYPs are reported
in human genome, but more than 90% of all therapeutic
drugs are metabolized by five isoforms i.e. CYP 3A4, 2D6,
1A2, 2C9 and 2C19 [3,4].
In the past, several methods have been developed for
predicting the metabolism of drug molecules using
machine learning techniques. Haji-Memonian et al. [5]
developed a CoMFA based method for predicting sub-
strate specificity of CYP2D6 isoform in which the models
were trained on 24 substrates. Blakin et al [6] used
Kohonen self-organizing maps and trained their models
on 33 molecules. Crivori and Proggesi et al. [7] used
experimental Km for developing quantitative structure
metabolism relationship (QSMRs) model. Manga et al.
[8] developed QSAR model for the determination of the
P450 enzyme predominantly responsible for a drug's
metabolism. Most of aforementioned approaches focused
on Michaelis constant Km values for the prediction of iso-
form specificity and were developed on small number of
substrates. Yap et al. [9] used SVM for developing model
for predicting inhibitors and substrate of three isoforms
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(i.e CYP 3A4, 2C9 and 2D6), where Ki value was used to
build SVM regression model.
There are two major problems in the existing methods;
i ) m os t  of  t he m deve l oped on lim i t ed n u m ber  of  s ub-
strate/drugs and ii) developed for limited number of iso-
forms. Recently Terfloth et al. [10] developed SVM based
QSAR model for predicting isoform specificity of three
major CYPs i.e CYP 3A4, 2C9 and 2D6. They used 146
compounds for training their models which was devel-
oped using multinomial logistic regression, decision tree,
or support vector machine (SVM). We manually exam-
ined 126 molecules out of 146 reported in DrugBank 2.5
[11,12] and found that 63 molecules were metabolized by
more than one isoform.
In this study, we have investigated the isoform specific-
ity of five major isoforms CYP 3A4, 2D6, 1A2, 2C9 and
2C19 that are responsible for metabolizing more than
90% drug molecules [3,4]. We have developed all models
on a clean and large dataset which was created from the
latest release of DrugBank. In the present study, we have
developed two types of model - i) single label models
where the model predicts best single metabolizing iso-
form for a drug molecule and ii) multi label models where
the model predicts a number of metabolizing isoform for
a drug. First time, we have developed model for two very
important Cytochrome P450 isoform, CYP1A2 and
CYP2C19. All the models were evaluated using cross-val-
idation techniques and on an independent dataset. First
time an attempt has been made to develop web server for
predicting metabolizing isoforms for a drug molecule.
Methods
Main dataset
All substrates that are metabolized by any of the follow-
ing isoform CYP 3A4, 2D6, 1A2, 2C9 and 2C19 were
obtained from DrugBank2.5 [11,12]. We have obtained a
total of 372 drug molecules where each of these mole-
cules was metabolized by at least one of the five isoforms.
I n  o r d e r  t o  c r e a t e  a n  e x c l u s i v e  d a t a s e t ,  w e  r e m o v e  a l l
those molecules that are metabolized by more than one
isoforms. Finally, we got a dataset of 216 drug molecules,
which consists of 111, 47, 29, 20 and 19 molecules metab-
olized through CYP 3A4, 2D6, 1A2, 2C9 and 2C19 iso-
forms respectively.
Independent dataset
We have created an independent dataset in order to eval-
uate performance without any bias. For this, we down-
loaded from DrugBank 146 molecules that were reported
to be metabolizing by one or more isoform used in this
study. This independent dataset consists of total 146 mol-
ecules, where 92, 74, 41, 47 and 49 molecules have meta-
bolic specificity for CYP 3A4, 2D6, 1A2, 2C9 and 2C19
isoform respectively.
Names of the molecules used in main dataset and inde-
pendent dataset are given in Additional file 1: Table S1 -
S6.
Molecular Structure and Descriptor Calculation
The 2D structure of each molecule was downloaded in
Mol file format from DrugBank. These 2D structures
were converted into 3D structure using CORINA soft-
ware [13], followed by energy minimization using Hamil-
tonian parameter AM1. Each minimized molecular
structure was treated as energetically preferred 3D struc-
ture for QSAR study. We used TSAR-3.3 [14] for comput-
ing 1D, 2D and 3D descriptors belonging to different
categories such as mass, surface area, volume, moment of
inertia, dipole, molar refractivity, lipophilicity, lipoles,
connectivity, electrostatic parameters. In addition,
ADMEWORKS Model Builder version 3.0 [15] were also
used for calculating of 2192 molecular descriptors cate-
gorized into different descriptor block such as topological
descriptors, constitutional descriptors, geometrical
descriptors, physiochemical and electrostatic descriptors.
The main categories are charge, charged polar surface
area (CPSA), CPSA-AM1, carbon type (CTYPE), molec-
ular distance edge descriptors, electro topological status
index, conformational flexibility, geometrical moments,
gravitation index descriptors, kappa index, path count,
molecular connectivity, molar refractivity substructure
descriptors, hydrogen bond specific descriptors, HMO
(Huckle molecular orbital) descriptors, MOPAC descrip-
tors. Finally we got total 2392 molecular descriptors
mainly computed using ADMEWORKS Model Builder
and TSAR.
Selection of Descriptors
One of the major challenges in a QSAR is the selection of
relevant molecular descriptors from large number of
descriptors. We removed descriptors; i) having more than
5% missing value, ii) contain less than 10% non-zero
value, iii) high correlation (≥ 0.9 Pearson's correlation)
with other descriptors and iv) multicollinearity (i.e.
descriptors are pair wise correlated in a multiple regres-
sion model such as stepwise MLR or leap and bound
MLR.) is more than 0.95. This way, numbers of molecular
descriptors were reduced to 113. The numbers of
descriptor were further reduced using genetic algorithm
(GA), a powerful variable selection approach [16,17].
Finally, we obtained 41 top ranking descriptors that were
used for developing SVM based QSAR models (Addi-
tional file 1: Table S7).
Cross-validation Techniques
The performances of QSAR models were evaluated using
leave one out cross-validation (LOOCV) and fivefold
cross-validation techniques. In LOOCV, model is trained
on N-1, where N is the total number of examples and per-Mishra et al. BMC Pharmacology 2010, 10:8
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formance is tested on the remaining examples. This pro-
cess is repeated in such a way that each example is used
once for testing. In five fold cross-validation, data set is
randomly divided in five partitions of similar size. The
training and testing were carries out 5 times, each time
using one set in testing and remaining four sets for train-
ing [18,19]. The model is rebuilt five times, one for each
fold ensuring that all molecules are used for testing once.
Figure of merits
In order to assess the performance of the models, we used
several parameters that include sensitivity, specificity,
accuracy, and MCC. Sensitivity is the percentage cover-
age of correctly predicted CYP isoform substrates; speci-
ficity is the percentage coverage of predicted non-CYP
isoform substrates; accuracy is the percentage of cor-
rectly predicted biotransformation of drug molecules and
MCC is the fitness function for model optimization.
These parameters can be represented by following equa-
tions:
Where TP and TN are correctly predicted positive and
negative examples; FP and FN are falsely predicted posi-
tive and negative examples. MCC is a Matthew's correla-
tion coefficient, which consider over and under
prediction; MCC 1 is regarded as a perfect prediction,
whereas 0 is regarded as random prediction.
One-versus-the-rest (1-v-r)
The prediction of substrate specificity of isoforms is a
multi-class classification problem, where as SVM is a
b i n a r y  c l a s s i f i e r .  I n  o r d e r  t o  h a n d l e  t h i s  p r o b l e m ,  w e
developed five models corresponding to five isoforms
used in this study, one SVM model for each isoform. For
example for developing a SVM model for CYP3A4, we
consider substrates of CYP3A4 as positive examples and
substrates of the rest of the isoforms as negative exam-
ples. Similarly for developing model for CYP2D6, sub-
s t r a t e s  o f  C Y P 2 D 6  u s e d  a s  p o s i t i v e  e x a m p l e s  a n d
substrates of the rest of the isoforms as negative exam-
ples.
Single Label Prediction
In case of single label prediction, we predict single best
isoform responsible for metabolizing a drug/substrate. In
other words for a substrate, we predict best isoform for
this substrate. Following steps are performed in order to
implement this single label prediction; i) one model for
each isoform is developed on the training dataset (using
1-v-r), ii) specificity of a substrate for each isoform is cal-
culated using above models and iii) a isoform having
highest specificity (SVM Score) for substrate is labeled as
predicted isoform. In this type of prediction, only one
class/label is assigned for a substrate. In order to assess
the performance of these models we compute two param-
eters called average accuracy and overall accuracy. In case
of average accuracy, we compute average of accuracy for
five isoforms (mean of five accuracies). In case of overall
accuracy, we compute overall percentage of correctly pre-
dicted substrates.
Multi-Label Prediction
It has been shown in previous studies that a drug can be
metabolized by more than one CYP isoform. In our inde-
pendent dataset we have substrates, which can be metab-
olized by more than one isoforms. Thus method has been
developed to predict multiple labels/isoforms for a sub-
strate. As described in one-versus-the-rest (1-v-r) sec-
tion, five models have been developed (one for each
isoform) and a default threshold was calculated for each
model. In this study, a default threshold is a SVM score
where performance of model is best in terms of MCC and
difference between sensitivity and specificity is mini-
mum. In order to predict isoform specificity of a sub-
strate, we have computed SVM score of the substrate
using each SVM model developed for five isoforms. If
SVM score is more than the default threshold for an iso-
form then that isoform is assigned as metabolizing the
substrate. It is possible that more than one isoforms are
predicted as metabolizing isoform for a substrate. This
type of prediction is called multi label prediction.
SVM Algorithm
In the present study a highly successful machine learning
technique, support vector machine (SVM) has been used
for the prediction of isoform specificity. SVM is based on
the structural risk minimization principle from statistical
learning theory [20]. The whole theory of SVM can be
simply described as follows: searching an optimal hyper-
plane satisfies the request of classification, and then use a
certain algorithm to make the margin of the separation
beside the optimal hyper-plane maximum while ensuring
the accuracy of correct classification [20,21]. SVM_light
software package has been used to develop SVM based
QSAR models. This software is freely downloaded from
http://www.cs.cornell.edu/People/tj/svm_light/. In this
study we tried various kernels like Radial Basis Function
(RBF), polynomial and linear kernel in order to achieve
best performance. The performance of models was opti-
mized using systematic variation of different SVM
parameters and kernels.
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Models using Weka
WEKA is a very popular and reliable package which is
frequently used in Bioinformatics and QSAR studies. We
used Weka version 3.6.0 [22] for developing different
models, which is a collection of machine-learning algo-
rithms. It supports several standard data mining tasks,
data pre-processing, clustering, classification, regression,
visualization, and feature selection. Here we used statisti-
cal and machine learning techniques implemented in
Weka to predict the isoform specificity of CYP such as:
(1) Random Forest algorithm: This is a meta-learner com-
prised of many individual trees, was designed to operate
quickly over large datasets and more importantly to be
diverse by using random samples to build each tree in the
forest [23]; SMOReg algorithm: Sequential Minimization
Optimization (SMO) [24,25] is a new algorithm for train-
ing SVM. This implementation globally replaced all miss-
ing values and transformed nominal attributes into
binary ones. It also normalized all attributes by default;
(3) Rotation Forest algorithm: This is a new classifiers for
constructing an ensemble of trees using random sub-
spaces and principal components transformation applied
to the input data [26]; (4) Simple logistic Algorithm: This
method build a logistic regression model using Logit-
Boost fitting (includes simple linear regression per attri-
bute), incorporates attribute selection by fitting simple
regression function in LogitBoost [27]; (5) BayesNet algo-
rithm: A BayesNet is a probabilistic graphical model
which represents a set of random variables and their con-
ditional independencies via a directed acyclic graph
(DAG). In this study BayesNet represents the probabilis-
tic relationships between different CYP isoforms and
their molecular descriptors [28,29]; (6) REPTree: This
algorithm build model on the basis of decision/regression
tree using information gain/feature reduction and prunes
it using reduced -error pruning (with backfitting). This
method considers all the attributes and missing value are
dealt with by splitting the corresponding instances into
pieces; (7) RBF Network : This method apply k-means
clustering to find the basis functions within each class.
The logistics regression's optimization algorithm auto-
matically determines the coefficients for each variable.
The magnitude of the coefficients are an indication to
their relative importance for predicting the class [30]; (8)
Multilayer perceptron: This is a feed forward artificial
neural network model that maps sets of input data onto a
set of appropriate output. It is a modification of the stan-
dard linear perceptron in that it uses three or more layers
of neurons (nodes) with nonlinear activation functions,
and is more powerful than the perceptron in that it can
distinguish data that is not linearly separable, or separa-
ble by a hyperplane [31]; (9) J48-IB1: This is a based on
the decision tree learning algorithm J48. A leaf may con-
tain a simple nearest neighbor classifier [32] using one
neighbor (i.e., IB1, in the terminology of Aha et al. [33]);
(10) NaiveBayes: This is a simple probabilistic classifier. It
assumes that every feature related to a class is indepen-
dent of each other [34]. This algorithm implements
Bayesian classification based on Bayes theorem of condi-
tional probability. The theorem is used to estimate the
probability of an example belonging to each of the possi-
ble classes of a classification problem [35]; (11) KStar:
This is an instance-based classifier. In this algorithm a
classification is based upon the class of those training
instances similar to it, as determined by some similarity
function [36] and (12) Logistic Regression: This algorithm
use multinomial logistic regression model with a ridge
estimator for classification [37].
Results
Performance on Main Dataset
The main dataset consists of total 216 substrates which
can be metabolized by one of the five CYP isoforms used
in this study. This dataset have 111, 47, 29, 20 and 19 mol-
ecules metabolized through isoform CYP 3A4, 2D6, 1A2,
2C9 and 2C19 respectively. As described in materials and
method that prediction of isoform is a multi class classifi-
cation as there are total five isoforms. SVM is a binary
classifier which predict a instance positive or negative
(yes or no). Thus we used one-versus-the-rest (1-v-r)
SVM approach where one model per isoform has been
developed. All models were developed using 41 selected
attributes/descriptors of substrate, as described in mate-
rials and method section.
SVM based Model for each Isoform
First we have developed SVM model for isoform CYP3A4
using SVM_light package. The dataset for this isoform
consists of 111 positive (substrates of CYP3A4) and 105
negative (rest of the substrates) examples. We have devel-
oped various models using different SVM parameters and
evaluated each model using five-fold cross-validation
technique. The performance of best model CYP3A4 is
shown in Table 1. A high performance (MCC 0.63 with
accuracy 81.42%) was achieved for this CYP3A4 isoform.
Similarly model was developed for isoform CYP2D6
where dataset consists of 47 positive (substrates of
CYP2D6) and 169 negative (rest of the substrates) exam-
ples. As shown in Table 1, we achieved best MCC 0.54
and accuracy 81.24% for isoform CYP2D6. Similarly,
models were developed for remaining isoform used in
this study, positive and negative examples used for each
isoform is shown by POE and NEE columns of Table 1. In
summary, we have achieved MCC 0.63, 0.54, 0.49, 0.40
and 0.15 for isoform CYP 3A4, 2D6, 1A2, 2C9 and 2C19
respectively. As shown in Table 1, the performance of a
model also depends on number of positive examples. The
model developed for CYP3A4 is best as it have nearly
equal number of positive and negative examples.Mishra et al. BMC Pharmacology 2010, 10:8
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Single Label Prediction
In above section, we have demonstrated the performance
of individual models developed for each isoform. In real-
ity, a user normally would like to know the best metabo-
lizing isoform for their substrate or drug molecule. Thus
there is a need to predict single label/isoform for a sub-
strate. In order to achieve single label prediction, first
individual SVM models were trained on training dataset
as described above. This way we got five models, one
model for each isoform. Secondly SVM score was calcu-
lated for each substrate in test dataset using five models.
In the third step, five SVM score of a substrate were com-
pared to detect isoform having highest SVM score.
Finally a metabolizing isoform was assigned for a sub-
strate based on the highest SVM score. It is important to
note that we are predicting best isoform for a compound.
This does not mean that the compound is non-substrate
for other isoforms. It is possible that this compound may
be metabolized by other isoform. In order to access the
performance, percent of correctly identified substrate of
each isoform is computed, which is shown as accuracy
(Table 2). We have achieved an accuracy of 78.76%,
83.19%, 87.61%, 91.15% and 89.38% for isoform CYP 3A4,
2D6, 1A2, 2C9 and 2C19 respectively, when evaluated
using fivefold cross-validation technique. Ideally one
need to evaluate the performance of models using
LOOCV technique, in this study fivefold cross-validation
technique has been used to save the computational time.
In order to see the effect on performance, we have also
evaluated the model using LOOCV. As shown in Table 2,
the overall accuracy of models improved marginally from
82.81% to 83.58% in case of LOOCV. The average accu-
racy has also increased slightly from 86.02% to 86.20%.
WEKA based Model
WEKA is powerful software that allows users to develop
models using various techniques [22]. We developed sin-
gle label prediction models, as described above using var-
ious machine learning techniques. The performance in
term of overall accuracy of the best model for each algo-
rithm is shown in Table 3. It was observed that Random-
Forest performed best among SMOreg, Random Forest,
Simple logostic, BayesNet, REPTree, RBF network, Mul-
tilayer perceptron, NaiveBayes, Logistic equation and
tree based IB1 & Kstar. Though RandomForest of WEKA
performed better than any other algorithm of WEKA but
its overall accuracy 69.47% was lower than overall accu-
racy 82.81% of SVM_light. All models were evaluated
using fivefold cross-validation technique.
Table 2: Percent of correctly predicted substrates (accuracy) belongs to different CYP isoforms where only single isoform 
was predicted for each substrate/molecule
CYP Isoform Accuracy (percent) Accuracy (percent)
(5 fold CV) (LOOCV)
CYP 1A2 78.76 80.53
CYP2C9 83.19 82.74
CYP2C19 87.61 84.96
CYP2D6 91.15 91.15
CYP3A4 89.38 91.59
Average Accuracy 86.02 86.20
Overall Accuracy 82.81 83.58
Table 1: Performance of SVM models developed for different CYP isoforms, all models evaluated using fivefold cross-
validation technique
Isoforms POE* NEE** Sensitivity Specificity Accuracy (%) MCC
CYP3A4 111 105 81.08 81.74 81.42 0.63
CYP2D6 47 169 74.47 83.24 81.24 0.54
CYP1A2 29 187 79.31 83.76 83.19 0.49
CYP2C9 20 196 70.00 85.92 84.51 0.40
CYP2C19 19 197 52.63 72.46 70.80 0.15
POE*: Positive Examples
NEE**: Negative Examples
Thres*: Threshold (Cutoff Value)Mishra et al. BMC Pharmacology 2010, 10:8
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Performance on Independent dataset
Over optimization is one of the major drawbacks in
cross-validation technique. Thus it is important to test
the performance of a newly developed model on an inde-
pendent dataset. As described in materials and method
section, independent dataset consists of total 146 mole-
cules. The number of molecules metabolized by isoform
CYP 3A4, 2D6, 3A2, 2C9 and 2C19 are 92, 74, 41, 47 and
49 respectively. The molecules in this dataset can be
metabolized by one or more than one CYP isoforms.
Simply, this dataset also consists of multi label/isoform
substrates; where as the main dataset exclusively consists
of single label substrates. First SVM score was calculated
for all molecules in independent dataset using SVM
model of CYP 3A4 and all molecules having SVM score
more than default threshold were predicted as molecule
metabolized by CYP 3A4. Similarly, SVM score was cal-
culated for remaining isoforms and predicted metaboliz-
ing isoform for each molecule. This is a multi label
prediction where more than one isoform may be pre-
dicted for a molecule. Finally, we have computed percent-
age of correctly predicted substrate (accuracy) for each
isoform. Out of 146 molecules, our models predicted 103
molecules correctly with an overall accuracy of 70.55%.
As shown in Table 4, we have achieved average accuracy
of 63.70% and the accuracy varies from 51.02% to 77.17%
for different isoforms.
Web server for Predicting Metabolizing
One of the major challenges for researchers working in
the field of drug discovery is to predict the metabolizing
isoform of a drug molecule. To the best of the author's
knowledge there is no free software or web server for pre-
dicting metabolizing isoforms of a substrate, though
number of methods have been developed in the past to
predict substrate specificity [4-10]. Most of the powerful
software packages commonly used for computing molec-
ular descriptors are commercial and licensed for limited
use. Thus it is not possible to use them for developing
web server. One of the major aims of our group is to pro-
mote open source software [38].
I n  t h i s  s t u d y ,  w e  h a v e  a l s o  d e v e l o p e d  m o d e l  u s i n g
molecular descriptors calculated using following software
packages; i) Chemistry Development Kit (CDK) a open
source java library [39,40] and ii) a descriptors calculation
software from Vlife [41]. Though Vlife is a commercial
package but we bought the right to use its descriptors in
our web server. Firstly we have computed 178 descriptors
using CDK on our main dataset. Secondly, 26 best molec-
ular descriptors were selected using WEKA based
GreedyStepWise and genetic search approaches. These
26 descriptors were used to develop SVM models based
on 1-v-r approach. We have achieved overall accuracy of
81.42% on main dataset; single label was predicted for
each substrate as described in above (single label predic-
tion) section. The performance was evaluated using five-
fold cross-validation technique. Similar approach was
adopted for models based of Vlife descriptors and
achieved maximum overall accuracy of 80.58% (Addi-
tional file 1: Table S9). As our models based on CDK
descriptors perform better than models based on Vlife,
we have developed and evaluated the performance of the
rest of the models on CDK descriptors (Additional file 1:
Table S10 - S11). The performance achieved using CDK
descriptors is nearly the same as that was achieved using
descriptors calculates using commercial software.
We have developed a server for predicting metabolizing
CYP isoform of a drug molecule/substrate, based on
SVM models developed using CDK descriptors. This
server is installed on Linux (Red Hat) operating system.
This is a user friendly web server, allows user to submit
Table 3: Overall accuracy achieved on main dataset, 
developed using different WEKA methods. Single label was 
predicted for each substrate and performance evaluated 
using five-fold cross-validation techniques
Methods Overall accuracy (percent)
Random Forest 69.47
SMOreg 69.03
Rotation Forest 68.58
Simple logistic 66.37
BayesNet 65.04
REPTree 64.60
RBF network 64.16
Multilayer perceptron 62.39
IB1 (tree) 58.41
NaïveBayes 57.96
KStar (tree) 56.20
Logistic equation 51.77
Table 4: Performance of SVM based isoform models on an 
Independent dataset. Multiple labels were assigned for 
substrates having SVM score more than default threshold 
for multiple isoform models
CYP Isoform Accuracy (percent)
CYP3A4 77.17
CYP2D6 66.22
CYP1A2 68.30
CYP2C9 55.32
CYP2C19 51.02
Average 63.70Mishra et al. BMC Pharmacology 2010, 10:8
http://www.biomedcentral.com/1471-2210/10/8
Page 7 of 9
their molecule in mol2/sdf/smile format or by online
drawing of molecule in JME editor. It also allows user to
predict single or multiple label/isoform for a molecule.
This server MetaPred is available free for public use from
http://crdd.osdd.net/raghava/metapred/.
Discussion
One of the most critical steps involved in discovering a
new drug molecule is to understand its ADMET (absorp-
tion, distribution, metabolism, excretion and toxicity)
properties.  In-silico  ADMET prediction may help to
detect and eliminate compounds with poor pharmacoki-
netic properties at early stage of the drug development
process. It is important to understand drug metabolism,
as it is important component of ADMET. The different
isoform of CYP involved in the phase I metabolism of
drug molecules. It is important to know which isoform is
responsible for the metabolism of a new drug molecule.
The ability to predict sites and rates of metabolism of new
substra t es is useful in drug deve lopmen t, as we ll as in
consideration of potential carcinogens and toxicants [42].
In this study, we have developed model for predicting
substrate specificity five major CYP 3A4, 2D6, 1A2, 2C9
and 2C19 isoform. One of the major features of this study
is clean and largest dataset. In a previous study, 146 sub-
strates have been used to develop model for three iso-
forms; as per latest version of DrugBank a large number
of molecules have specificity for more than one isoform.
In our study we have used 216 drug molecules for five iso-
form, each molecule metabolized only by one isoform. It
is important to have clean and large dataset for develop-
ing highly accurate isoform model. We have also evalu-
ated the performance of our models on independent
dataset extracted from DrugBank. Independent dataset
consists of 146 molecules which interact with at least one
of the five isoform; this dataset also includes molecules
which can be metabolizing by more than one isoform. In
summary, we have used largest possible data for our study
from latest version of DrugBank.
One of the important factors which play a critical role
in developing QSAR model is the number of molecular
descriptors. As described in materials and method sec-
tion, we have computed more than 2000 different types of
descriptors encompassing almost all the properties of
molecules. Another important step in development of
models is the selection of best descriptors. Thus, all
highly correlated, irrelevant molecular descriptor were
removed; finally only the best 41 descriptors were used to
develop QSAR models. Most of the powerful techniques
commonly used for developing QSAR model (like SVM)
are binary classifier whereas classification of isoform sub-
strates is a multi class classification problem. In order to
solve this problem, 1-v-r approach has been used where
five QSAR models have been developed for five isoform,
one model for each isoform. One can develop QSAR
model using number of techniques/algorithms. In this
study first we have developed SVM based models, imple-
mented using SVM_light package. As shown in Table 1, a
reasonably high performance (MCC ≥ 0.4) was achieved
for most of the isoform except for CYP 2C19. The perfor-
mance for a model depends on number of substrates;
unfortunately number of substrates is very small for most
of the isoform. Though we have taken largest possible
dataset but this dataset is not sufficient enough for devel-
oping very reliable models. These types of model can be
improved significantly by training them on large experi-
mental data.
It is important for a user to predict best CYP isoform
responsible for metabolizing their drug molecule. Thus
we have developed single-label prediction, where our
method predicts single best isoform responsible for
metabolizing a substrate/molecule. As shown in Table 2,
reasonable high overall and average accuracy was
achieved. It is also observed that the performance of five-
fold cross-validation is as good as LOOCV. Thus in most
of the study we have used fivefold cross-validation in
order to save computational time. WEKA is one the pow-
erful package which allows implementing a large number
of algorithms, thus we have developed various QSAR
model using these algorithms. As shown in Table 3, a rea-
sonable overall accuracy was achieved for number of
models. It was observed that SVM based QSAR models
developed using SVM_light performed better than other
m o d e l s .  T h u s  i n  r e s t  o f  o u r  s t u d y  w e  h a v e  d e v e l o p e d
QSAR models for isoforms using SVM. It has been shown
in the past that the cross-validation techniques suffer
from over optimization, thus methods were also validated
on an independent dataset. In case of evaluation of inde-
pendent dataset, we have used multi label/isoform pre-
diction approach where more than one isoform were also
predicted for a substrate. It is because the independent
dataset set also have substrates which are metabolized by
more than one isoform. As shown in T able 4, we have
obtained reasonably high accuracy on this dataset.
As shown in results section, SVM based models devel-
oped using 41 selected descriptors achieved very high
accuracy. In order to compute these descriptors we have
used commercial software. We have limited permissions
to use these commercial due to license conditions. Thus
we cannot provide service to community using these
packages. In the past, number of methods has been devel-
oped for predicting substrate specificity of CYP isoforms
but there is no web server for predicting isoform specific-
ity. These studies have limited use for public. A large
number of web servers have been developed in the field
of bioinformatics, most of bioinformatics journal encour-
age authors to develop web server for public. In contrast
there are very limited web servers. One of the objectivesMishra et al. BMC Pharmacology 2010, 10:8
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of our group is to encourage open source software.
Recently we developed few servers in the field of
chemoinformatics [43,44]. In order to develop web server
for predicting metabolizing isoform of a drug molecule,
we explore possibility. We found open source software
CDK that allow calculating 178 molecular descriptors
(one tenth of commercial descriptors). We have devel-
oped QSAR models based on SVM using 26 best descrip-
tors of CDK. It has been observed that performance of
models based on CDK descriptors is as good as we have
achieved using descriptors obtained from commercial
package. We developed a web server MetaPred for pre-
dicting isoform responsible for metabolizing a drug mol-
ecule, in order to promote open source software in
chemoinformatics and to help the researcher working in
the field of drug discovery.
Conclusions
In this study, attempt has been made to predict substrate
specificity of CYP 3A4, 2D6, 1A2, 2C9 and 2C19 isoforms
using different approaches. We achieved an average accu-
racy more than 85% and overall accuracy more than 82%
using single prediction approach. The dataset used in this
study consists of latest and approved drug molecules.
Thus the models developed in this study are more accu-
rate and reliable, as they have been trained on large and
clean dataset. First time models have been developed for
five CYP isoforms. It has been demonstrated that models
developed using CDK molecular descriptors are as good
as models developed using descriptors calculated by
commercial software. Based on this study we developed a
web server MetaPred for predicting metabolizing isoform
of a molecule. In long term this server will be useful for
researchers working in the field of drug discovery. This
study demonstrates that it is possible to develop free web
servers in the field of chemoinformatics. This will
encourage other researchers to develop web server for
public use, which may lead to decrease the cost of discov-
ering new drug molecules.
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